Portal de Periódicos da CAPES

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques

2021; Elsevier BV; Volume: 2; Issue: 4 Linguagem: Inglês

10.1016/j.xcrm.2021.100230

2666-3791

Ahmed O. Hassan, Friederike Feldmann, Haiyan Zhao, David T. Curiel, Atsushi Okumura, Tsing-Lee Tang-Huau, James Brett Case, Kimberly Meade‐White, Julie Callison, Rita E. Chen, Jamie Lovaglio, Patrick W. Hanley, Dana Scott, Daved H. Fremont, Heinz Feldmann, Michael Diamond,

Immunotherapy and Immune Responses

The deployment of a vaccine that limits transmission and disease likely will be required to end the coronavirus disease 2019 (COVID-19) pandemic. We recently described the protective activity of an intranasally administered chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike (S) protein (ChAd-SARS-CoV-2-S [chimpanzee adenovirus-severe acute respiratory syndrome-coronavirus-2-S]) in the upper and lower respiratory tracts of mice expressing the human angiotensin-converting enzyme 2 (ACE2) receptor. Here, we show the immunogenicity and protective efficacy of this vaccine in non-human primates. Rhesus macaques were immunized with ChAd-Control or ChAd-SARS-CoV-2-S and challenged 1 month later by combined intranasal and intrabronchial routes with SARS-CoV-2. A single intranasal dose of ChAd-SARS-CoV-2-S induces neutralizing antibodies and T cell responses and limits or prevents infection in the upper and lower respiratory tracts after SARS-CoV-2 challenge. As ChAd-SARS-CoV-2-S confers protection in non-human primates, it is a promising candidate for limiting SARS-CoV-2 infection and transmission in humans.